

# Nestlé India Limited

(CIN : L15202DL1959PLC003786)

Nestlé House

Jacaranda Marg

'M'Block, DLF City, Phase – II

Gurugram – 122002, Haryana

Phone: 0124 – 3940000

E-mail: investor@in.nestle.com

Website: www.nestle.in



**PKR:SG: 76:24**

**1<sup>st</sup> August 2024**

## **BSE Limited (BSE)**

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai – 400001

BSE Scrip Code: 500790

## **National Stock Exchange of India Limited (NSE)**

Exchange Plaza, Plot No. C/1,

G Block, Bandra-Kurla Complex,

Bandra (East), Mumbai - 400 051

NSE Symbol: NESTLEIND

**Subject: Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”): Disclosure of change in the Senior Management of the Company**

Dear Madam/ Sir,

Pursuant to appointment of Ms. Mansi Khanna as Chief Operating Officer of Dr. Reddy's and Nestlé Health Science Limited (“JV Company”), in line with the definitive agreement dated 25<sup>th</sup> April 2024 (“JV Agreement”) to form a joint venture between Nestlé India Limited (“Nestlé India”) and Dr. Reddy's Laboratories Limited (“DRL”) and Business Transfer Agreement (“BTA”) entered between Nestlé India and the JV Company, this is to inform you that Ms. Mansi Khanna ceased to be Head of Nestlé Health Science Business of the Company (Senior Management Personnel) effective from 1<sup>st</sup> August 2024.

The details of the JV Agreement and BTA has been separately communicated to the stock exchanges vide our letter no. PKR:SG 52:24 dated 25<sup>th</sup> April 2024 and PKR:SG: 75:24 dated 1<sup>st</sup> August 2024. Details in accordance with the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 is given in Annexure - I to this letter.

This is in compliance with Regulation 30 read with Para A of Part A of Schedule III of the Listing Regulations.

The above is for your information and record.

Thanking you,

Yours truly,

**NESTLÉ INDIA LIMITED**

**PRAMOD KUMAR RAI**

**COMPANY SECRETARY AND COMPLIANCE OFFICER**

Encl.: as above

# Nestlé India Limited

(CIN : L15202DL1959PLC003786)

Nestlé House

Jacaranda Marg

'M'Block, DLF City, Phase – II

Gurugram – 122002, Haryana

Phone: 0124 – 3940000

E-mail: investor@in.nestle.com

Website: www.nestle.in



## Annexure - I

Details as required in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023.

S. No.	Details of events that need to be provided	Information of such event(s)
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Pursuant to appointment of Ms. Mansi Khanna as Chief Operating Officer of Dr. Reddy's and Nestlé Health Science Limited ("JV Company"), in line with the definitive agreement dated 25 <sup>th</sup> April 2024 ("JV Agreement") to form a joint venture between Nestlé India Limited ("Nestlé India") and Dr. Reddy's Laboratories Limited ("DRL") and Business Transfer Agreement ("BTA") entered between Nestlé India and the JV Company, Ms. Mansi Khanna ceased to be Head of Nestlé Health Science Business of the Company (Senior Management Personnel) effective from 1 <sup>st</sup> August 2024.
2.	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment/ re-appointment;	1 <sup>st</sup> August 2024
3.	Brief Profile (in case of appointment)	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable